Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
VistaGen Therapeutics (VTGN)
NASDAQ:VTGN
RESEARCH TOOLSreports
Earnings Data
Report Date
Jul 01, 2025TBA Not Confirmed
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.51Last Year’s EPS
-0.35Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 13, 2025
|% Change Since: 0.70%
|Next Earnings Date:Jul 01, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment due to the significant progress in clinical trials, a robust and diverse product pipeline, and a strong financial position. However, increased R&D expenses and net loss were notable concerns.Company Guidance
During VistaGen Therapeutics' third-quarter fiscal year 2025 corporate update call, the company provided guidance on several key metrics and developments. The company reported a significant increase in research and development expenses, totaling $11.3 million for the quarter ended December 31, 2024, compared to $4.5 million in the prior year, attributed to advancements in their Palisade Phase 3 program for fasedienol in social anxiety disorder (SAD) and IND-enabling programs for itruvone and PH80. General and administrative expenses rose slightly to $4.0 million. The net loss for the quarter was $14.1 million, up from $6.4 million the previous year. Financially, VistaGen reported $88.6 million in cash, cash equivalents, and marketable securities as of the end of 2024. The company expressed confidence in delivering top-line results from its ongoing Palisade 3 and 4 Phase 3 trials later in 2025, which, together with Palisade 2, may support a new drug application submission to the FDA. Additionally, VistaGen highlighted progress in its broader pipeline, including the initiation of exploratory studies and plans for further clinical development in other therapeutic areas.Progress in Clinical Trials for Fasedienol
Palisade Phase 3 program for fasedienol in treating social anxiety disorder (SAD) is advancing as planned, with Palisade 3 and Palisade 4 expected to report top-line results in 2025. Initiation and enrollment of the first subjects in an exploratory Phase 2 repeat-dose study of fasedienol in SAD were also announced.
Diverse and Innovative Product Pipeline
VistaGen has five clinical-stage intranasal pherine product candidates, all with positive Phase 2 data, and one with Phase 3 positive clinical results. The pipeline's reliance on nose-to-brain neurocircuitry offers a non-systemic and rapid-onset treatment approach.
Strong Financial Position
As of December 31, 2024, VistaGen had $88.6 million in cash, cash equivalents, and marketable securities.
---
VTGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VTGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 13, 2025 | $2.85 | $2.97 | +4.21% |
| Nov 07, 2024 | $3.12 | $3.14 | +0.64% |
| Aug 13, 2024 | $3.39 | $3.28 | -3.24% |
| Jun 11, 2024 | $3.77 | $3.69 | -2.12% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does VistaGen Therapeutics (VTGN) report earnings?
VistaGen Therapeutics (VTGN) is schdueled to report earning on Jul 01, 2025, TBA Not Confirmed.
What is VistaGen Therapeutics (VTGN) earnings time?
VistaGen Therapeutics (VTGN) earnings time is at Jul 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VTGN EPS forecast?
VTGN EPS forecast for the fiscal quarter 2025 (Q4) is -0.51.
---